The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2001
year mood +0.20 · +0.00 to +0.36 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb Mar Apr May Jun Jul Aug +0.36 Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.30+0.30+0.20+0.20+0.20+0.20+0.20+0.36+0.00+0.10+0.10+0.20

Healthcare sentiment is neutral this month, as the withdrawal of Bayer's cholesterol drug Baycol due to patient deaths weighed on sector confidence, particularly in pharmaceuticals. The incident triggered a sharp decline in Bayer's shares, highlighting drug safety risks and regulatory scrutiny. However, broader market stability and underlying demand for healthcare services offset some of the negative momentum, preventing a wider downturn.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2001
Aug
Bayer pulls cholesterol drug Baycol after deaths; shares plunge cbsnews.com →

Bayer withdrew its statin worldwide after links to fatal muscle breakdown, wiping roughly a fifth off its market value. The recall previewed the litigation and safety risk that would haunt global pharma.

Dec
FDA Rejects ImClone's Erbitux, Stock Plummets Amid Scandal foxnews.com →

The FDA rejected ImClone's cancer drug Erbitux due to incomplete trial data and regulatory violations, triggering a sharp stock decline and investigations into insider trading and executive misconduct. Key players include ImClone, Bristol-Myers Squibb, and the Waksal family, with significant market implications as investor confidence collapsed and partnerships unraveled. The event sparked congressional and SEC probes, reshaping oversight in biotech drug approvals.